相关实验视频
Updated: Mar 12, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
在晚期慢性肝病中对肥胖的管理
Cyrielle Caussy1,2, Sven M Francque3,4
1Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, 69495 Pierre-Bénite, France.
JHEP reports : innovation in hepatology
|March 11, 2026
概括
肥胖是一个全球性的健康挑战,与MASLD和MetALD等肝脏疾病有关. 通过改变生活方式,手术或新的药物来管理肥胖,可以改善晚期慢性肝病患者的结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 公共卫生 公共卫生
背景情况:
- 肥胖是一个重要的全球健康问题.
- 肥胖与代谢功能障碍相关的脂肪性肝病 (MASLD) 和代谢功能障碍和酒精相关的肝病 (MetALD) 密切相关.
- 在患有晚期慢性肝病 (ACLD) 的患者中观察到更高的肥胖率,这会对预后产生负面影响.
研究的目的:
- 为了突出肥胖和肝病进展之间的关联.
- 讨论身体质量指数 (BMI) 作为可修改的风险因素的作用.
- 探索新兴的治疗策略,以控制肝脏疾病患者的肥胖.
主要方法:
- 关于肥胖和肝脏疾病的文献综述.
- 对ACLD中肥胖患病率的流行病学数据的分析.
- 审查目前和新兴的肥胖治疗选择.
主要成果:
- 增加的BMI是跨病因的肝病进展的可修改风险因素.
- 现在可以使用有效的抗肥胖药物.
- 治疗性生活方式改变和减肥手术是已知的管理选择.
结论:
- 肥胖管理对于改善MASLD,MetALD和ACLD患者的治疗结果至关重要.
- 包括生活方式改变,手术和新药在内的个性化治疗策略是必不可少的.
- 解决肥胖症为缓解肝病进展和改善患者预后提供了一个有希望的途径.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
452
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
452
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
260
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
260
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
342
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
342
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
Drug Dosing: Obese Patients
325
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Atherosclerosis III: Management
541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541

